CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial Novel predictors of late lumen enlargement in distal reference segments after successful recanalization of coronary chronic total occlusion Usefulness of minimum stent cross sectional area as a predictor of angiographic restenosis after primary percutaneous coronary intervention in acute myocardial infarction (from the HORIZONS-AMI Trial IVUS substudy) The Year in Cardiovascular Medicine 2020: Imaging: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of imaging are Fausto Pinto, José Luis Zamorano and Chiara Bucciarelli-Ducci. Judy Ozkan speaks with them Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Accuracy of Fractional Flow Reserve Derived From Coronary Angiography Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block Sex differences in left main coronary artery stenting: Different characteristics but similar outcomes for women compared with men

Original Research2019 Aug 6. doi: 10.7326/M19-1337.

JOURNAL:Ann Intern Med. Article Link

Comparative Accuracy of Focused Cardiac Ultrasonography and Clinical Examination for Left Ventricular Dysfunction and Valvular Heart Disease: A Systematic Review and Meta-analysis

Marbach JA, Almufleh A, Di Santo P et al. Keywords: cardiac ultrasonography; valvular heart disease

ABSTRACT


BACKGROUND - Incorporating focused cardiac ultrasonography (FoCUS) into clinical examination could improve the diagnostic yield of bedside patient evaluation.

 

PURPOSE - To compare the accuracy of FoCUS-assisted clinical assessment versus clinical assessment alone for diagnosing left ventricular dysfunction or valvular disease in adults having cardiovascular evaluation.

 

DATA SOURCES - English-language searches of MEDLINE, Embase, and Web of Science from 1 January 1990 to 23 May 2019 and review of reference citations.

 

STUDY SELECTION - Eligible studies were done in patients having cardiovascular evaluation; compared FoCUS-assisted clinical assessment versus clinical assessment alone for the diagnosis of left ventricular systolic dysfunction, aortic or mitral valve disease, or pericardial effusion; and used transthoracic echocardiography as the reference standard.

 

DATA EXTRACTION - Three study investigators independently abstracted data and assessed study quality.

 

DATA SYNTHESIS - Nine studies were included in the meta-analysis. The sensitivity of clinical assessment for diagnosing left ventricular dysfunction (left ventricular ejection fraction <50%) was 43% (95% CI, 33% to 54%), whereas that of FoCUS-assisted examination was 84% (CI, 74% to 91%). The specificity of clinical assessment was 81% (CI, 65% to 90%), and that of FoCUS-assisted examination was 89% (CI, 85% to 91%). The sensitivities of clinical assessment and FoCUS-assisted examination for diagnosing aortic or mitral valve disease (of at least moderate severity) were 46% (CI, 35% to 58%) and 71% (CI, 63% to 79%), respectively. Both the clinical assessment and the FoCUS-assisted examination had a specificity of 94% (CI, 91% to 96%).

 

LIMITATION - Evidence was scant, persons doing ultrasonography had variable skill levels, and most studies had unclear or high risk of bias.

 

CONCLUSION - Clinical examination assisted by FoCUS has greater sensitivity, but not greater specificity, than clinical assessment alone for identifying left ventricular dysfunction and aortic or mitral valve disease; FoCUS-assisted examination may help rule out cardiovascular pathology in some patients, but it may not be sufficient for definitive confirmation of cardiovascular disease suspected on physical examination.

 

PRIMARY FUNDING SOURCE - None. (PROSPERO: CRD42019124318).